abstract |
FIELD: medicine, pharmaceutics. n SUBSTANCE: group of inventions relates to medicine, namely to haematology and can be applied in treatment of disorders, associated with haemorrhage. Method in accordance with invention includes introduction of factor VIIa chimeric polypeptide to subject, where said factor VIIa chimeric polypeptide includes domain EGF-2 and factor VII catalytic domain; GLA domain, selected from the group, consisting of factor VII GLA domain, factor IX GLA domain and protein S GLA domain; and EGF-1 domain, selected from the group, consisting of factor IX EGF-1 domain and protein S EGF-1 domain. Factor VIIa chimeric polypeptide in accordance with invention includes EGF-2 domain and factor VII catalytic domain; protein S GLA domain; and EGF-1 domain, selected from the group, consisting of protein S EGF-1 domain and factor IX EGF-1 domain. Molecule of nucleic acid by invention codes factor VIIa chimeric polypeptide. Inventions also deal with vector, including molecule of nucleic acid, cell, including factor VIIa chimeric polypeptide and cell, including vector. n EFFECT: application of inventions makes it possible to reduce doses of introduced protein and attenuate undesirable side effects. n 11 cl, 7 dwg, 5 ex |